Remission of primary hyperparathyroidism on the background of drug therapy: A case from clinical practice
https://doi.org/10.62751/2713-0177-2025-6-1-11
Abstract
Primary hyperparathyroidism is an endocrine disease characterized by persistent disturbance of phosphorus-calcium metabolism due to primary pathology of the parathyroid glands. Surgical treatment is the only method that allows achieving persistent remission of the disease and preventing the development of symptoms associated with hypercalcemia, improving the condition of bone tissue and kidneys. Conservative treatment does not allow achieving an equal effect. There are isolated cases of spontaneous remission of primary hyperparathyroidism after drug therapy in medical reviews. This article presents a case of long-term observation of a patient with primary hyperparathyroidism, who achieved persistent remission against the background of conservative treatment. Phosphorus-calcium metabolism and parathyroid hormone levels normalized, densitometry indicators improved, and parathyroid gland formations regressed. The period of remission of primary hyperparathyroidism is more than 30 months.
About the Author
E. S. Gracheva
City Clinical Hospital named after V.P. Demikhov of the Moscow City Department of Health
Russian Federation
Russian Federation
Ekaterina S. Grachevа – endocrinologist
Moscow
References
1. Мокрышева Н.Г., Еремкина А.К., Мирная С.С. соавт. Клинические рекомендации по первичному гиперпаратиреозу, краткая версия. Проблемы эндокринологии. 2021; 67(4): 94–124. doi: 10.14341/probl12801.
2. Bilezikian JP, Cusano NE, Khan AA et al. Primary hyperparathyroidism. Nat Rev Dis Primers. 2016; 2: 16033. doi: 10.1038/nrdp.2016.33.
3. Clarke BL. Asymptomatic primary hyperparathyroidism. Front Horm Res. 2019; 51: 13–22. doi: 10.1159/000491035.
4. Peacock M, Bolognese MA, Borofsky M et al, Cinacalcet treatment of primary hyperparathyroidism: Biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009; 94(12): 4860–67. doi: 10.1210/jc.2009-1472.
5. Свечкарева И.Р., Колбин А.С. Перспективы использования аллостерических препаратов в реальной клинической практике. Реальная клиническая практика: данные и доказательства. 2023; 3(4): 15–21. doi: 10.37489/2782-3784-myrwd-43.
Review
For citations:
Gracheva E.S. Remission of primary hyperparathyroidism on the background of drug therapy: A case from clinical practice. FOCUS. Endocrinology. 2025;6(1):79-84. (In Russ.) https://doi.org/10.62751/2713-0177-2025-6-1-11
Views:
48
Email this article 